Skip to content

Are QALYs #ableist?

As many of us who have had to review submitted journal articles, thesis defenses, grant applications, white papers, and even published literature know, providing feedback on something that is poorly conceived is much harder than providing feedback on something well done.

This is going to be hard.

Who is ValueOurHealth?

The video above comes from the website of “ValueOurHealth.org”; I would tell you more about them, but there is no “About Us” menu item on the website. However, the website indicates that they are a group of patient organizations concerned about:

“The use of flawed, discriminatory value assessments [that] could threaten access to care for patients with chronic illnesses and people with disabilities.”

In particular, who find issue with value assessments that

“place a value on the life of a human based on their health status and assume every patient will respond the same way to treatments.”

QALYs, according to these concerned patient groups, assign a value to human beings. People with lower values (like Jessica, in the video above), then, will be denied coverage because their life is “valued less than someone in perfect health” which means “less value is also placed on treating” them. (Many will be quick to notice that health states and QALYs are used interchangeably here. I try to explain why below.)

It’s not like this is a well-intended rogue group who simply misunderstands the concept of a QALY, requires someone to send them a polite email, and then we can all move on. Other groups have also asserted that QALYs unfairly discriminate against the aged and disabled, and include AimedAlliance, Alliance for Patient Access, Institute for Patient Access, Alliance for Aging Research, and Global Liver Institute. There are likely many more patient groups that abhor QALYs (and definite articles/determiners, it seems) out there, and are justifiably concerned about patient access to therapy. But these are all the ones I could find through a quick search and sitting from my perch in Canada.

Why do they hate QALYs?

One can infer pretty quickly that ValueOurHealth and their illustrative message is largely motivated by another very active organization, the “Partnership to Improve Patient Care” (PIPC). The video, and the arguments about “assigning QALYs” to people, seem to stem from a white paper produced by the PIPC, which in turn cites a very nicely written paper by Franco Sassi (of Imperial College London), that explains QALY and DALY calculations for researchers and policymakers.

The PIPC white paper, in fact, uses the very same calculation provided by Prof. Sassi to illustrate the impact of preventing a case of tuberculosis. However, unlike Prof. Sassi’s illustrative example, the PIPC fails to quantify the QALYs gained by the intervention. Instead they simply focus on the QALYs an individual who has tuberculosis for 6 months will experience. (0.36, versus 0.50, for those keeping score). After some further discussion about problems with measuring health states, the PIPC white paper then skips ahead to ethical problems with QALYs central to their position, citing a Value in Health paper by Erik Nord and colleagues. One of the key problems with the QALY according to the PIPC and argued in the Nord paper goes as follows:

“Valuing health gains in terms of QALYs means that life-years gained in full health—through, for instance, prevention of fatal accidents in people in normal health—are counted as more valuable than life-years gained by those who are chronically ill or disabled—for instance, by averting fatal episodes in people with asthma, heart disease, or mental illness.”

It seems the PIPC assume the lower number of QALYs experienced by those who are sick equates with the value of lives to payers. Even more interestingly, Prof. Nord’s analysis says nothing about costs. While those who are older have fewer QALYs to potentially gain, they also incur fewer costs. This is why, contrary to the assertion of preventing accidents in healthy people, preventive measures may offer a similar value to treatments when both QALYS and costs are considered.

It is also why an ICER review showed that alemtuzumab is good value in individuals requiring second-line treatment for relapse-remitting multiple sclerosis (1.34 QALYs can be gained compared to the next best alternative and at a lower cost then comparators), while a policy of annual mammography screening of similarly aged (i.e., >40) healthy women is of poor economic value (0.036 QALYs can be gained compared to no screening at an additional cost of $5,500 for every woman). Mammography provides better value in older individuals. It is not unlike fracture prevention and a myriad of other interventions in healthy, asymptomatic people in this regard. Quite contrary to the assertion of these misinformed groups, many interventions represent increasingly better value in frail, disabled, and older patients. Relative risks create larger yields when baseline risks are high.

None of this is to say that QALYs (and incremental cost-effectiveness ratios) do not have problems. And the PIPC, at the very least, should be commended for trying to advance alternative metrics, something that very few critics have offered. Instead, the PIPC and like-minded organizations are likely trapped in a filter bubble. They know there are problems with QALYs, and they see expensive and rare disease treatments being valued harshly. So, ergo, blame the QALY. (Note to PIPC: it is because the drugs are expensive, relative to other life-saving things, not because of your concerns about the QALY.) They then see that others feel the same way, which means their concerns are likely justified. A critique of QALYs issued by the Pioneer Institute identifies many of these same arguments. One Twitterer, a disabled Massachusetts lawyer “alive because of Medicaid” has offered further instruction for the QALY-naive.

https://twitter.com/mattbc/status/1159937845425033222?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1159937845425033222&ref_url=https%3A%2F%2Fpublish.twitter.com%2F%3Fquery%3Dhttps%253A%252F%252Ftwitter.com%252Fmattbc%252Fstatus%252F1159937845425033222%26widget%3DTweet

What to do about it?

As a friend recently told me, not everyone is concerned with the QALY. Some don’t like what they see as a rationing approach promoted by the Institute for Clinical and Economic Review (ICER) assessments. Some hate the QALY. Some hate both. Last year, Joshua T. Cohen, Dan Ollendorf, and Peter Neumann published their own blog entry on the effervescing criticism of ICER, even allowing the PIPC head to have a say about QALYs. They then tried to set the record straight with these thoughts:

While we applaud the call for novel measures and to work with patient and disability advocates to understand attributes important to them, there are three problems with PIPC’s position.

First, simply coming up with that list of key attributes does not address how society should allocate finite resources, or how to price a drug given individual or group preferences.

Second, the diminished weight QALYs assign to life with disability does not represent discrimination. Instead, diminished weight represents recognition that treatments mitigating disability confer value by restoring quality of life to levels typical among most of the population.

Finally, all value measures that inform allocation of finite resources trade off benefits important to some patients against benefits potentially important to others. PIPC itself notes that life years not weighted for disability (e.g., the equal value life-year gained, or evLYG, introduced by ICER for sensitivity analysis purposes) do not award value for improved quality of life. Indeed, any measure that does not “discriminate” against patients with disability cannot award treatments credit for improving their quality of life. Failing to award that credit would adversely affect this population by ruling out spending on such improvements.

Certainly a lot more can be said here.

But for now, I am more curious what others have to say…

By

  • Don Husereau

    Academic Health Economists' Blog Contributor. Naysayer. Edu-tainer. ORCID: 0000-0002-4416-6876 donhusereau.com

We now have a newsletter!

Sign up to receive updates about the blog and the wider health economics world.

0 0 votes
Article Rating
Subscribe
Notify of
guest

1 Comment
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
trackback
3 years ago

[…] To read the blog post and watch the video, click here. […]

1
0
Join the conversation, add a commentx
()
x
%d bloggers like this: